Evaluation of radiomics as a predictor of efficacy and the tumor immune microenvironment in anti‐PD‐1 mAb treated recurrent/metastatic squamous cell carcinoma of the head and neck patients
Background We retrospectively evaluated radiomics as a predictor of the tumor microenvironment (TME) and efficacy with anti‐PD‐1 mAb (IO) in R/M HNSCC. Methods Radiomic feature extraction was performed on pre‐treatment CT scans segmented using 3D slicer v4.10.2 and key features were selected using L...
Gespeichert in:
| Veröffentlicht in: | Head & neck 2025-01, Vol.47 (1), p.129-138 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 138 |
|---|---|
| container_issue | 1 |
| container_start_page | 129 |
| container_title | Head & neck |
| container_volume | 47 |
| creator | Zandberg, Dan P. Zenkin, Serafettin Ak, Murat Mamindla, Priyadarshini Peddagangireddy, Vishal Hsieh, Ronan Anderson, Jennifer L. Delgoffe, Greg M. Menk, Ashely Skinner, Heath D. Duvvuri, Umamaheswar Ferris, Robert L. Colen, Rivka R. |
| description | Background
We retrospectively evaluated radiomics as a predictor of the tumor microenvironment (TME) and efficacy with anti‐PD‐1 mAb (IO) in R/M HNSCC.
Methods
Radiomic feature extraction was performed on pre‐treatment CT scans segmented using 3D slicer v4.10.2 and key features were selected using LASSO regularization method to build classification models with XGBoost algorithm by incorporating cross‐validation techniques to calculate accuracy, sensitivity, and specificity. Outcome measures evaluated were disease control rate (DCR) by RECIST 1.1, PFS, and OS and hypoxia and CD8 T cells in the TME.
Results
Radiomics features predicted DCR with accuracy, sensitivity, and specificity of 76%, 73%, and 83%, for OS 77%, 86%, 70%, PFS 82%, 75%, 89%, and in the TME, for high hypoxia 80%, 88%, and 72% and high CD8 T cells 91%, 83%, and 100%, respectively.
Conclusion
Radiomics accurately predicted the efficacy of IO and features of the TME in R/M HNSCC. Further study in a larger patient population is warranted. |
| doi_str_mv | 10.1002/hed.27878 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_11635745</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>3143193531</sourcerecordid><originalsourceid>FETCH-LOGICAL-c3348-3cad4b463880830c01e21347d972500416b40a7c9f20a01a4356dfb0a25cd0703</originalsourceid><addsrcrecordid>eNp1kktuFDEQhlsIRB6w4ALIEpuw6Ey57X6tUJQMBCkSLGBt1dhuxqFtT2z3oNlxBI6Us3AS3JkQARKSZVuqr_6_qlRF8YLCKQWoFmutTqu2a7tHxSGFvi2B8fbx_OesZNDyg-IoxmsAYA2vnhYHrIcO-qY7LG6XWxwnTMY74gcSUBlvjYwE8yGboJWRyYc5pofBSJQ7gk6RtNYkTTZHjLWT0yQnBa_d1gTvrHaJGJfBZH5-__HxIl-U2LMVSUFj0ooELacQMrawOmFMuQBJ4s2E1k-RSD2ORGKQxnmLs_dst9ao7rydll_JJqfk_PiseDLgGPXz-_e4-Px2-en8srz68O79-dlVKRnjXckkKr7iDes66BhIoLqieUqqb6sagNNmxQFb2Q8VIFDkrG7UsAKsaqmgBXZcvNnrbqaV1Upm74Cj2ARjMeyERyP-jjizFl_8VlDasLrldVY4uVcI_mbSMQlr4twqOp27Fgy6XF5V97PZq3_Qaz8Fl_sTjHJGe1YzmqnXeypPPsagh4dqKIh5MUReDHG3GJl9-Wf5D-TvTcjAYg98M6Pe_V9JXC4v9pK_ABARx2U</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>3143193531</pqid></control><display><type>article</type><title>Evaluation of radiomics as a predictor of efficacy and the tumor immune microenvironment in anti‐PD‐1 mAb treated recurrent/metastatic squamous cell carcinoma of the head and neck patients</title><source>MEDLINE</source><source>Access via Wiley Online Library</source><creator>Zandberg, Dan P. ; Zenkin, Serafettin ; Ak, Murat ; Mamindla, Priyadarshini ; Peddagangireddy, Vishal ; Hsieh, Ronan ; Anderson, Jennifer L. ; Delgoffe, Greg M. ; Menk, Ashely ; Skinner, Heath D. ; Duvvuri, Umamaheswar ; Ferris, Robert L. ; Colen, Rivka R.</creator><creatorcontrib>Zandberg, Dan P. ; Zenkin, Serafettin ; Ak, Murat ; Mamindla, Priyadarshini ; Peddagangireddy, Vishal ; Hsieh, Ronan ; Anderson, Jennifer L. ; Delgoffe, Greg M. ; Menk, Ashely ; Skinner, Heath D. ; Duvvuri, Umamaheswar ; Ferris, Robert L. ; Colen, Rivka R.</creatorcontrib><description>Background
We retrospectively evaluated radiomics as a predictor of the tumor microenvironment (TME) and efficacy with anti‐PD‐1 mAb (IO) in R/M HNSCC.
Methods
Radiomic feature extraction was performed on pre‐treatment CT scans segmented using 3D slicer v4.10.2 and key features were selected using LASSO regularization method to build classification models with XGBoost algorithm by incorporating cross‐validation techniques to calculate accuracy, sensitivity, and specificity. Outcome measures evaluated were disease control rate (DCR) by RECIST 1.1, PFS, and OS and hypoxia and CD8 T cells in the TME.
Results
Radiomics features predicted DCR with accuracy, sensitivity, and specificity of 76%, 73%, and 83%, for OS 77%, 86%, 70%, PFS 82%, 75%, 89%, and in the TME, for high hypoxia 80%, 88%, and 72% and high CD8 T cells 91%, 83%, and 100%, respectively.
Conclusion
Radiomics accurately predicted the efficacy of IO and features of the TME in R/M HNSCC. Further study in a larger patient population is warranted.</description><identifier>ISSN: 1043-3074</identifier><identifier>ISSN: 1097-0347</identifier><identifier>EISSN: 1097-0347</identifier><identifier>DOI: 10.1002/hed.27878</identifier><identifier>PMID: 39080968</identifier><language>eng</language><publisher>Hoboken, USA: John Wiley & Sons, Inc</publisher><subject>Adult ; Aged ; artificial intelligence ; CD8 antigen ; Disease control ; Female ; Head and neck carcinoma ; Head and Neck Neoplasms - diagnostic imaging ; Head and Neck Neoplasms - drug therapy ; Head and Neck Neoplasms - immunology ; Head and Neck Neoplasms - pathology ; Head and Neck Neoplasms - therapy ; head and neck squamous cell carcinoma ; Humans ; Hypoxia ; imaging ; Immune Checkpoint Inhibitors - therapeutic use ; immunotherapy ; Lymphocytes T ; machine learning ; Male ; Metastases ; Middle Aged ; Neoplasm Recurrence, Local - diagnostic imaging ; Original ; pembrolizumab ; Population studies ; Predictive Value of Tests ; Programmed Cell Death 1 Receptor - antagonists & inhibitors ; Radiomics ; Regularization methods ; Retrospective Studies ; Sensitivity analysis ; Squamous cell carcinoma ; Squamous Cell Carcinoma of Head and Neck - diagnostic imaging ; Squamous Cell Carcinoma of Head and Neck - drug therapy ; Squamous Cell Carcinoma of Head and Neck - immunology ; Squamous Cell Carcinoma of Head and Neck - pathology ; Squamous Cell Carcinoma of Head and Neck - therapy ; Tomography, X-Ray Computed - methods ; Treatment Outcome ; treatment response ; Tumor Microenvironment ; Tumors</subject><ispartof>Head & neck, 2025-01, Vol.47 (1), p.129-138</ispartof><rights>2024 The Author(s). published by Wiley Periodicals LLC.</rights><rights>2024 The Author(s). Head & Neck published by Wiley Periodicals LLC.</rights><rights>2024. This article is published under http://creativecommons.org/licenses/by-nc-nd/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><cites>FETCH-LOGICAL-c3348-3cad4b463880830c01e21347d972500416b40a7c9f20a01a4356dfb0a25cd0703</cites><orcidid>0000-0002-1002-8301</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://onlinelibrary.wiley.com/doi/pdf/10.1002%2Fhed.27878$$EPDF$$P50$$Gwiley$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://onlinelibrary.wiley.com/doi/full/10.1002%2Fhed.27878$$EHTML$$P50$$Gwiley$$Hfree_for_read</linktohtml><link.rule.ids>230,314,780,784,885,1417,27924,27925,45574,45575</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/39080968$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Zandberg, Dan P.</creatorcontrib><creatorcontrib>Zenkin, Serafettin</creatorcontrib><creatorcontrib>Ak, Murat</creatorcontrib><creatorcontrib>Mamindla, Priyadarshini</creatorcontrib><creatorcontrib>Peddagangireddy, Vishal</creatorcontrib><creatorcontrib>Hsieh, Ronan</creatorcontrib><creatorcontrib>Anderson, Jennifer L.</creatorcontrib><creatorcontrib>Delgoffe, Greg M.</creatorcontrib><creatorcontrib>Menk, Ashely</creatorcontrib><creatorcontrib>Skinner, Heath D.</creatorcontrib><creatorcontrib>Duvvuri, Umamaheswar</creatorcontrib><creatorcontrib>Ferris, Robert L.</creatorcontrib><creatorcontrib>Colen, Rivka R.</creatorcontrib><title>Evaluation of radiomics as a predictor of efficacy and the tumor immune microenvironment in anti‐PD‐1 mAb treated recurrent/metastatic squamous cell carcinoma of the head and neck patients</title><title>Head & neck</title><addtitle>Head Neck</addtitle><description>Background
We retrospectively evaluated radiomics as a predictor of the tumor microenvironment (TME) and efficacy with anti‐PD‐1 mAb (IO) in R/M HNSCC.
Methods
Radiomic feature extraction was performed on pre‐treatment CT scans segmented using 3D slicer v4.10.2 and key features were selected using LASSO regularization method to build classification models with XGBoost algorithm by incorporating cross‐validation techniques to calculate accuracy, sensitivity, and specificity. Outcome measures evaluated were disease control rate (DCR) by RECIST 1.1, PFS, and OS and hypoxia and CD8 T cells in the TME.
Results
Radiomics features predicted DCR with accuracy, sensitivity, and specificity of 76%, 73%, and 83%, for OS 77%, 86%, 70%, PFS 82%, 75%, 89%, and in the TME, for high hypoxia 80%, 88%, and 72% and high CD8 T cells 91%, 83%, and 100%, respectively.
Conclusion
Radiomics accurately predicted the efficacy of IO and features of the TME in R/M HNSCC. Further study in a larger patient population is warranted.</description><subject>Adult</subject><subject>Aged</subject><subject>artificial intelligence</subject><subject>CD8 antigen</subject><subject>Disease control</subject><subject>Female</subject><subject>Head and neck carcinoma</subject><subject>Head and Neck Neoplasms - diagnostic imaging</subject><subject>Head and Neck Neoplasms - drug therapy</subject><subject>Head and Neck Neoplasms - immunology</subject><subject>Head and Neck Neoplasms - pathology</subject><subject>Head and Neck Neoplasms - therapy</subject><subject>head and neck squamous cell carcinoma</subject><subject>Humans</subject><subject>Hypoxia</subject><subject>imaging</subject><subject>Immune Checkpoint Inhibitors - therapeutic use</subject><subject>immunotherapy</subject><subject>Lymphocytes T</subject><subject>machine learning</subject><subject>Male</subject><subject>Metastases</subject><subject>Middle Aged</subject><subject>Neoplasm Recurrence, Local - diagnostic imaging</subject><subject>Original</subject><subject>pembrolizumab</subject><subject>Population studies</subject><subject>Predictive Value of Tests</subject><subject>Programmed Cell Death 1 Receptor - antagonists & inhibitors</subject><subject>Radiomics</subject><subject>Regularization methods</subject><subject>Retrospective Studies</subject><subject>Sensitivity analysis</subject><subject>Squamous cell carcinoma</subject><subject>Squamous Cell Carcinoma of Head and Neck - diagnostic imaging</subject><subject>Squamous Cell Carcinoma of Head and Neck - drug therapy</subject><subject>Squamous Cell Carcinoma of Head and Neck - immunology</subject><subject>Squamous Cell Carcinoma of Head and Neck - pathology</subject><subject>Squamous Cell Carcinoma of Head and Neck - therapy</subject><subject>Tomography, X-Ray Computed - methods</subject><subject>Treatment Outcome</subject><subject>treatment response</subject><subject>Tumor Microenvironment</subject><subject>Tumors</subject><issn>1043-3074</issn><issn>1097-0347</issn><issn>1097-0347</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2025</creationdate><recordtype>article</recordtype><sourceid>24P</sourceid><sourceid>WIN</sourceid><sourceid>EIF</sourceid><recordid>eNp1kktuFDEQhlsIRB6w4ALIEpuw6Ey57X6tUJQMBCkSLGBt1dhuxqFtT2z3oNlxBI6Us3AS3JkQARKSZVuqr_6_qlRF8YLCKQWoFmutTqu2a7tHxSGFvi2B8fbx_OesZNDyg-IoxmsAYA2vnhYHrIcO-qY7LG6XWxwnTMY74gcSUBlvjYwE8yGboJWRyYc5pofBSJQ7gk6RtNYkTTZHjLWT0yQnBa_d1gTvrHaJGJfBZH5-__HxIl-U2LMVSUFj0ooELacQMrawOmFMuQBJ4s2E1k-RSD2ORGKQxnmLs_dst9ao7rydll_JJqfk_PiseDLgGPXz-_e4-Px2-en8srz68O79-dlVKRnjXckkKr7iDes66BhIoLqieUqqb6sagNNmxQFb2Q8VIFDkrG7UsAKsaqmgBXZcvNnrbqaV1Upm74Cj2ARjMeyERyP-jjizFl_8VlDasLrldVY4uVcI_mbSMQlr4twqOp27Fgy6XF5V97PZq3_Qaz8Fl_sTjHJGe1YzmqnXeypPPsagh4dqKIh5MUReDHG3GJl9-Wf5D-TvTcjAYg98M6Pe_V9JXC4v9pK_ABARx2U</recordid><startdate>202501</startdate><enddate>202501</enddate><creator>Zandberg, Dan P.</creator><creator>Zenkin, Serafettin</creator><creator>Ak, Murat</creator><creator>Mamindla, Priyadarshini</creator><creator>Peddagangireddy, Vishal</creator><creator>Hsieh, Ronan</creator><creator>Anderson, Jennifer L.</creator><creator>Delgoffe, Greg M.</creator><creator>Menk, Ashely</creator><creator>Skinner, Heath D.</creator><creator>Duvvuri, Umamaheswar</creator><creator>Ferris, Robert L.</creator><creator>Colen, Rivka R.</creator><general>John Wiley & Sons, Inc</general><general>Wiley Subscription Services, Inc</general><scope>24P</scope><scope>WIN</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7QP</scope><scope>7TK</scope><scope>K9.</scope><scope>7X8</scope><scope>5PM</scope><orcidid>https://orcid.org/0000-0002-1002-8301</orcidid></search><sort><creationdate>202501</creationdate><title>Evaluation of radiomics as a predictor of efficacy and the tumor immune microenvironment in anti‐PD‐1 mAb treated recurrent/metastatic squamous cell carcinoma of the head and neck patients</title><author>Zandberg, Dan P. ; Zenkin, Serafettin ; Ak, Murat ; Mamindla, Priyadarshini ; Peddagangireddy, Vishal ; Hsieh, Ronan ; Anderson, Jennifer L. ; Delgoffe, Greg M. ; Menk, Ashely ; Skinner, Heath D. ; Duvvuri, Umamaheswar ; Ferris, Robert L. ; Colen, Rivka R.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c3348-3cad4b463880830c01e21347d972500416b40a7c9f20a01a4356dfb0a25cd0703</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2025</creationdate><topic>Adult</topic><topic>Aged</topic><topic>artificial intelligence</topic><topic>CD8 antigen</topic><topic>Disease control</topic><topic>Female</topic><topic>Head and neck carcinoma</topic><topic>Head and Neck Neoplasms - diagnostic imaging</topic><topic>Head and Neck Neoplasms - drug therapy</topic><topic>Head and Neck Neoplasms - immunology</topic><topic>Head and Neck Neoplasms - pathology</topic><topic>Head and Neck Neoplasms - therapy</topic><topic>head and neck squamous cell carcinoma</topic><topic>Humans</topic><topic>Hypoxia</topic><topic>imaging</topic><topic>Immune Checkpoint Inhibitors - therapeutic use</topic><topic>immunotherapy</topic><topic>Lymphocytes T</topic><topic>machine learning</topic><topic>Male</topic><topic>Metastases</topic><topic>Middle Aged</topic><topic>Neoplasm Recurrence, Local - diagnostic imaging</topic><topic>Original</topic><topic>pembrolizumab</topic><topic>Population studies</topic><topic>Predictive Value of Tests</topic><topic>Programmed Cell Death 1 Receptor - antagonists & inhibitors</topic><topic>Radiomics</topic><topic>Regularization methods</topic><topic>Retrospective Studies</topic><topic>Sensitivity analysis</topic><topic>Squamous cell carcinoma</topic><topic>Squamous Cell Carcinoma of Head and Neck - diagnostic imaging</topic><topic>Squamous Cell Carcinoma of Head and Neck - drug therapy</topic><topic>Squamous Cell Carcinoma of Head and Neck - immunology</topic><topic>Squamous Cell Carcinoma of Head and Neck - pathology</topic><topic>Squamous Cell Carcinoma of Head and Neck - therapy</topic><topic>Tomography, X-Ray Computed - methods</topic><topic>Treatment Outcome</topic><topic>treatment response</topic><topic>Tumor Microenvironment</topic><topic>Tumors</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Zandberg, Dan P.</creatorcontrib><creatorcontrib>Zenkin, Serafettin</creatorcontrib><creatorcontrib>Ak, Murat</creatorcontrib><creatorcontrib>Mamindla, Priyadarshini</creatorcontrib><creatorcontrib>Peddagangireddy, Vishal</creatorcontrib><creatorcontrib>Hsieh, Ronan</creatorcontrib><creatorcontrib>Anderson, Jennifer L.</creatorcontrib><creatorcontrib>Delgoffe, Greg M.</creatorcontrib><creatorcontrib>Menk, Ashely</creatorcontrib><creatorcontrib>Skinner, Heath D.</creatorcontrib><creatorcontrib>Duvvuri, Umamaheswar</creatorcontrib><creatorcontrib>Ferris, Robert L.</creatorcontrib><creatorcontrib>Colen, Rivka R.</creatorcontrib><collection>Wiley Online Library (Open Access Collection)</collection><collection>Wiley Online Library Free Content</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Calcium & Calcified Tissue Abstracts</collection><collection>Neurosciences Abstracts</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Head & neck</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Zandberg, Dan P.</au><au>Zenkin, Serafettin</au><au>Ak, Murat</au><au>Mamindla, Priyadarshini</au><au>Peddagangireddy, Vishal</au><au>Hsieh, Ronan</au><au>Anderson, Jennifer L.</au><au>Delgoffe, Greg M.</au><au>Menk, Ashely</au><au>Skinner, Heath D.</au><au>Duvvuri, Umamaheswar</au><au>Ferris, Robert L.</au><au>Colen, Rivka R.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Evaluation of radiomics as a predictor of efficacy and the tumor immune microenvironment in anti‐PD‐1 mAb treated recurrent/metastatic squamous cell carcinoma of the head and neck patients</atitle><jtitle>Head & neck</jtitle><addtitle>Head Neck</addtitle><date>2025-01</date><risdate>2025</risdate><volume>47</volume><issue>1</issue><spage>129</spage><epage>138</epage><pages>129-138</pages><issn>1043-3074</issn><issn>1097-0347</issn><eissn>1097-0347</eissn><abstract>Background
We retrospectively evaluated radiomics as a predictor of the tumor microenvironment (TME) and efficacy with anti‐PD‐1 mAb (IO) in R/M HNSCC.
Methods
Radiomic feature extraction was performed on pre‐treatment CT scans segmented using 3D slicer v4.10.2 and key features were selected using LASSO regularization method to build classification models with XGBoost algorithm by incorporating cross‐validation techniques to calculate accuracy, sensitivity, and specificity. Outcome measures evaluated were disease control rate (DCR) by RECIST 1.1, PFS, and OS and hypoxia and CD8 T cells in the TME.
Results
Radiomics features predicted DCR with accuracy, sensitivity, and specificity of 76%, 73%, and 83%, for OS 77%, 86%, 70%, PFS 82%, 75%, 89%, and in the TME, for high hypoxia 80%, 88%, and 72% and high CD8 T cells 91%, 83%, and 100%, respectively.
Conclusion
Radiomics accurately predicted the efficacy of IO and features of the TME in R/M HNSCC. Further study in a larger patient population is warranted.</abstract><cop>Hoboken, USA</cop><pub>John Wiley & Sons, Inc</pub><pmid>39080968</pmid><doi>10.1002/hed.27878</doi><tpages>10</tpages><orcidid>https://orcid.org/0000-0002-1002-8301</orcidid><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1043-3074 |
| ispartof | Head & neck, 2025-01, Vol.47 (1), p.129-138 |
| issn | 1043-3074 1097-0347 1097-0347 |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_11635745 |
| source | MEDLINE; Access via Wiley Online Library |
| subjects | Adult Aged artificial intelligence CD8 antigen Disease control Female Head and neck carcinoma Head and Neck Neoplasms - diagnostic imaging Head and Neck Neoplasms - drug therapy Head and Neck Neoplasms - immunology Head and Neck Neoplasms - pathology Head and Neck Neoplasms - therapy head and neck squamous cell carcinoma Humans Hypoxia imaging Immune Checkpoint Inhibitors - therapeutic use immunotherapy Lymphocytes T machine learning Male Metastases Middle Aged Neoplasm Recurrence, Local - diagnostic imaging Original pembrolizumab Population studies Predictive Value of Tests Programmed Cell Death 1 Receptor - antagonists & inhibitors Radiomics Regularization methods Retrospective Studies Sensitivity analysis Squamous cell carcinoma Squamous Cell Carcinoma of Head and Neck - diagnostic imaging Squamous Cell Carcinoma of Head and Neck - drug therapy Squamous Cell Carcinoma of Head and Neck - immunology Squamous Cell Carcinoma of Head and Neck - pathology Squamous Cell Carcinoma of Head and Neck - therapy Tomography, X-Ray Computed - methods Treatment Outcome treatment response Tumor Microenvironment Tumors |
| title | Evaluation of radiomics as a predictor of efficacy and the tumor immune microenvironment in anti‐PD‐1 mAb treated recurrent/metastatic squamous cell carcinoma of the head and neck patients |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-26T00%3A03%3A10IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Evaluation%20of%20radiomics%20as%20a%20predictor%20of%20efficacy%20and%20the%20tumor%20immune%20microenvironment%20in%20anti%E2%80%90PD%E2%80%901%20mAb%20treated%20recurrent/metastatic%20squamous%20cell%20carcinoma%20of%20the%20head%20and%20neck%20patients&rft.jtitle=Head%20&%20neck&rft.au=Zandberg,%20Dan%20P.&rft.date=2025-01&rft.volume=47&rft.issue=1&rft.spage=129&rft.epage=138&rft.pages=129-138&rft.issn=1043-3074&rft.eissn=1097-0347&rft_id=info:doi/10.1002/hed.27878&rft_dat=%3Cproquest_pubme%3E3143193531%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=3143193531&rft_id=info:pmid/39080968&rfr_iscdi=true |